HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 291/2/G267    most recent 00496.2005v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Fujii, R. Articles by Watanabe, M. Search for Related Content PubMed PubMed Citation Articles by Fujii, R. Articles by Watanabe, M.

HORMONES AND SIGNALING

FTY720 suppresses CD4⁺CD44^highCD62L^– effector memory T cell-mediated colitis

Department of Gastroenterology and Hepatology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan

Submitted 20 October 2005 ; accepted in final form 9 March 2006

FTY720, a sphingosine-derived immunomodulator, causes immunosuppression via enhancement of lymphocyte sequestration into secondary lymphoid organs, thereby preventing their antigen-activated T cell egress to sites of inflammation. FTY720 is highly effective in inhibiting autoimmunity in various animal models. However, there is little known about how FTY720 controls the migration property of memory T cells. Here, we demonstrated that FTY720 prevents the development of colitis induced by the adoptive transfer of lamina propria (LP) colitogenic effector memory CD4⁺ T cells (T_EM cells; CD45RB^lowCD44^highCD62L^–) into severe combined immunodeficiency (SCID) mice and suppresses interferon-, interleukin-2, and tumor necrosis factor- production by LP CD4⁺ T cells. The numbers of spleen, peripheral blood, mesenteric lymph node, and LP CD4⁺ T cells in FTY720-treated mice were significantly reduced compared with those in control mice. Notably, LP CD4⁺ T_EM cells as well as splenic CD4⁺CD45RB^high T cells expressed several spingosine-1-phosphate receptors that are targets for FTY720. Furthermore, FTY720 also prevented the development of colitis induced by the adoptive transfer of splenic CD4⁺CD45RB^high T cells into SCID mice. Collectively, the present data indicate that FTY720 treatment may offer the potential not only to prevent the onset of disease but also to treat memory T cell-mediated autoimmune diseases including inflammatory bowel diseases.

therapy; migration; I cell

This article has been cited by other articles:

				J. Song, C. Matsuda, Y. Kai, T. Nishida, K. Nakajima, T. Mizushima, M. Kinoshita, T. Yasue, Y. Sawa, and T. Ito A Novel Sphingosine 1-Phosphate Receptor Agonist, 2-Amino-2-propanediol Hydrochloride (KRP-203), Regulates Chronic Colitis in Interleukin-10 Gene-Deficient Mice J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 276 - 283. [Abstract] [Full Text] [PDF]

				J.-R. Nofer, M. Bot, M. Brodde, P. J. Taylor, P. Salm, V. Brinkmann, T. van Berkel, G. Assmann, and E. A.L. Biessen FTY720, a Synthetic Sphingosine 1 Phosphate Analogue, Inhibits Development of Atherosclerosis in Low-Density Lipoprotein Receptor Deficient Mice Circulation, January 30, 2007; 115(4): 501 - 508. [Abstract] [Full Text] [PDF]